Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety study of ceftibuten and polymyxin B combination in healthy volunteers
RBR-8gbnr2xPhase 1Not yet recruiting
- Sponsor
- UniEVANGÉLICA
- Start
- Sep 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ceftibuten and polymyxin B in bacterial disease (4 arms), sponsored by UniEVANGÉLICA. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
ceftibutenpolymyxin B
03
Conditions
bacterial disease
Beyond the preview
Go deeper on RBR-8gbnr2x.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-8gbnr2x.